Human Microbiome Therapeutics Market Size and Share Expected to Cross USD 3,917.01 Million By 2032, at 22.7% CAGR: Polaris Market Research


NEW YORK, Jan. 11, 2024 /PRNewswire/ — A latest research report [115+] pages with 360-Degree visibility, titled “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs); By Therapeutic Areas; By Indication; By Approach; By Region; Segment Forecast, 2023 – 2032” published by Polaris Market Research in its research repository.


The global human microbiome therapeutics market size and share is predicted to grow from USD 508.70 million in 2022 to USD 3,917.01 million in 2032. It is anticipated to grow at a Compound Annual Growth Rate (CAGR) of 22.7% from 2023 to 2032, according to the latest report by Polaris Market Research.

A Quick Review

  • What is Human Microbiome Therapeutics? How Big is Human Microbiome Therapeutics Size & Share?

The human body is the abode of a massive and manifold faction of microorganisms comprising bacteria, fungi, protozoa, and viruses. Broadly, it is approximated that over 10,000 genera of microorganisms inhabit the human microbiota and that there might be an additional eight million distinct genes linked with several microbiomes in the human body. The rapidly rising demand for human microbiome therapeutics market can be attributed to the fact that therapeutic exploitation of microbiome is speedily advancing area and data indicates that cure proficient of overriding a defaced dysbiotic microbiome are successful in handling specific human illnesses.

Human microbiome therapeutics market growth can be attributed to growing research and comprehension of the human microbiome’s part in health and illness, which has propelled the advancement of contemporary therapies. The market is also pushed by the growing pervasiveness of the state of affairs, such as gastrointestinal disarray, autoimmune illnesses, and metabolic disorders, which are imagined to be impacted by the microbiome.

Request Free Sample Copy of Human Microbiome Therapeutics Market Research Report @ 

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)

Our Sample Report May Includes:

  • 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
  • 115+ Pages Research Report (Inclusion of Updated Research).
  • Provide Chapter-wise guidance on Request.
  • 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends.
  • Includes Updated List of table & figures.
  • Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.

Which is the Largest Human Microbiome Therapeutics in the World?

  • 16S Technologies
  • 4D Pharma PLC
  • 5QBD-Biotech
  • BiomX
  • Biotagenics
  • Carbiotix
  • ClearB Therapeutics
  • Commense
  • CoreBiome
  • DermBiont
  • E.I. du Pont de Nemours and Company
  • Embion Technologies
  • Enterome Bioscience
  • Exeliom Biosciences
  • Ferring Pharmaceuticals
  • Finch Therapeutics
  • GNUbiotics Sciences
  • GoodBelly
  • GoodGut
  • Holobiome
  • Hyggut
  • Igen Biolab Group
  • Lactobio
  • Oxidien Pharmaceuticals, LLC
  • Second Genome
  • Seres Therapeutics
  • Synlogic
  • UBiome
  • Vedanta Biosciences
  • ViThera Pharmaceuticals

Purchase a Full Detail Report With Complete TOC @ 

Important Highlights from the Report

  • Therapeutic exploitation of microbiome is a speedily advancing area, and data indicates that cure proficient of overriding a defaced dysbiotic microbiome is successful in handling specific human illnesses causing expansion of the market.
  • The growing research and comprehension of the human microbiome’s part in health and illness has propelled the advancement of contemporary therapies, which is pushing the market.
  • The human microbiome therapeutics market segmentation is primarily segmented based on product, therapeutic area, indication, approach, and region.
  • North America has dominated the market with the largest share in 2022.

Market’s Prime Determinants of Growth, Trends, and Opportunities

Increasing cases of dysbiosis: The market is encountering notable growth foremost pushed by growing cases of diseases connected to dysbiosis in the gut microbiota. The human microbiome therapeutics market size is expanding due to a sizeable allotment of funds for biological drug detection, and research is pushing the growth. There is an increasing demand for accurate, reliable, and rapid therapies to inscribe hepatic encephalopathy, phenylketonuria, C. difficile infection, and multidrug-resistant urinary system infections. This worldwide demand is anticipated to commit to the proliferation of the market.

Progressive treatment nominations: The bestowing of stray drug nominations and progressive treatment nominations for human microbiome cure is expected to speed up the initiation of contemporary pharmaceuticals in the industry. Human microbiome therapeutics market sales are soaring as the industry carries notable probability for augmentation as there are presently over 120 medication contenders in several junctures of discovery, which will be devoted to the expansion of the market.

Inquire more about this report before purchase @

(Inquire a report quote OR available discount offers to the sales team before purchase.)

Trends and Opportunities

Advancement of microbiome-dependent therapeutics: Sequencing technologies and bioinformatics progression have improvised the capacity to identify and operate the microbiome, easing the advancement of more earmarked and productive therapies. Further administrative bodies have offered suggestions and structures to reinforce the advancement and consent of microbiome-dependant therapeutics, additionally pushing market growth.

Segmental Analysis

  • The Infectious Disease Segment Witnessed a Sharp Surge

Based on the therapeutic area, the infectious disease segment witnessed a sharp surge. Human microbiome therapeutics market demand is on the rise due to the growing consciousness of pessimistic results of antibiotic utilization and organic flora, which has highlighted the requirement for selected treatments for infectious illnesses. Further, the growing pervasiveness of diseases created by microbial dysbiosis because of antibiotic therapy and the increasing aggregate of clinical studies for advancing microbiome-dependent therapeutics is pushing the augmentation of this segment.

As a consequence, progression in diagnostic instruments and a profound comprehension of premature diagnosis push the market growth. The occurrence of infectious diseases in both advanced and surfacing nations will commit to the victory of the infectious disease diagnostic industry. Additionally, the growing prescription assessments for diagnostic tests referred to transmissible diseases and an increasing concentration on preventive care is anticipated to push the demand for the market throughout the forecast period.

  • The Probiotic Segment Dominated the Market

Based on product, the probiotic segment dominated the market. Human microbiome therapeutics market trends include probiotics such as bacteria and yeast provide several health advantages when consumed. These advantages traverse from reinforcing digestion and immune basis to fostering comprehensive well-being. Presently, compact molecule treatments carry the biggest market share within the industry. Compact molecule treatments indicate therapeutic substances comprising minuscule organic molecules broadly utilized in medical practice. The extensive use of compact molecule treatments has translated to a notable market presence.

Request Customized Copy of Report @

(We customize your report according to your research need. Ask our sales team for report customization.)

Human Microbiome Therapeutics Market: Report Scope

Report Attribute


Revenue forecast in 2032

USD 3,917.01 Million

Market size value in 2023

USD 623.20 Million

Expected CAGR Growth

22.7% from 2023 – 2032

Base Year


Forecast Year

2023 – 2032

Top Market Players

DermBiont, BiomX, Ferring Pharmaceuticals, 5QBD-Biotech, GoodBelly, Finch Therapeutics, UBiome, ClearB Therapeutics, Lactobio, CoreBiome, GoodGut, Biotagenics, 4D Pharma PLC

Segments Covered

By Product, By Therapeutic Areas, By Indication, By Approach, By Region

Customization Options

Customized purchase options are available to meet any research needs. Explore customized purchase options


Regional Insights

North America: This region held the largest human microbiome therapeutics market share due to the fact that human microbiome therapeutics is prospering and carries an important position within the healthcare industry. This region is spearheading research and development with strong funding, clinical trials, and partnerships pushing progression. The rooted healthcare framework, robust official framework, and the existence of detrimental illnesses offer a productive ground for the development of the market in North America. Prominent market players and biotechnology firms devoted to microbiome research commit to the market’s expansion, additionally pushing innovation and commodification endeavors.

Browse the Detail Report “Human Microbiome Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Probiotics, Prebiotics, Medical Foods, Prescription Drugs); By Therapeutic Areas; By Indication; By Approach; By Region; Segment Forecast, 2023 – 2032” with in-depth TOC:            

For Additional Information OR Media Enquiry, Please Mail At: [email protected] 

Key Questions Answered in the Report

  • What is the current and expected human microbiome therapeutics market value?

Ans: The current market value of the human microbiome therapeutics market is USD 623.20 million, and the expected market value is USD 3,917.01 million.

  • At what CAGR is the market expected to grow during the forecast period?

Ans: The market is expected to grow at a CAGR of 22.7% during the forecast period.

  • Which factors are driving the market growth?

Ans: Factors such as increasing cases of dysbiosis and progressive treatment nominations are driving the market.

  • Which segment accounts for the largest human microbiome therapeutics market share?

Ans: The infectious disease segment accounted for the largest market share.

Polaris Market Research has segmented the Human Microbiome Therapeutics market report based on product, therapeutic areas, indication, approach, and region:

Human Microbiome Therapeutics, Product Outlook (Revenue – USD Million, 2019 – 2032)

  • Probiotics
  • Prebiotics
  • Medical Foods
  • Prescription Drugs

Human Microbiome Therapeutics, Therapeutic Areas Outlook (Revenue – USD Million, 2019 – 2032)

  • Autoimmune Disorders
  • Dental Disorders
  • Digestive and Gastrointestinal Disorders
  • Dermatological Disorders
  • Infectious Disease
  • Metabolic Disorders
  • Oncology
  • Others

Human Microbiome Therapeutics, Indications Outlook (Revenue – USD Million, 2019 – 2032)

  • Acne Vulgaris
  • Atopic Dermatitis
  • Clostridium difficile Infection
  • Colorectal Cancer
  • Diabetes
  • Inflammatory Bowel Disease (IBD)
  • Lactose Intolerance
  • Lung Cancer
  • Non-alcoholic steatohepatitis (NASH)
  • Obesity
  • Coeliac Disease

Human Microbiome Therapeutics, Approach Outlook (Revenue – USD Million, 2019 – 2032)

  • Small Molecule Therapies
  • Single Strain Whole Bacteria
  • Microbial Consortia
  • Genetically Modified Single Strain Bacteria
  • Phage Cocktail
  • Microbial Ecosystems

Human Microbiome Therapeutics, Regional Outlook (Revenue – USD Million, 2019 – 2032)

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Netherlands
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Indonesia
    • Malaysia
  • Latin America
    • Argentina
    • Brazil
    • Mexico
  • Middle East & Africa
    • UAE
    • Saudi Arabia
    • Israel
    • South Africa

Browse More Research Reports:

  • Endobronchial Valves Market Size and Share Outlook, 2024-2032
  • Automotive Hypervisors Market Size and Share Outlook, 2024-2032
  • Solar Control Window Films Market Size and Share Outlook, 2024-2032
  • Aircraft Catering Vehicle Market Size and Share Outlook, 2024-2032
  • HERG Screening Market Size and Share Outlook, 2024-2032

About Polaris Market Research

Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semi-conductors and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high growth markets, emerging business environments and latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced and extremely qualified team of experts comprising SMEs, analysts and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.


Likhil G

30 Wall Street

8th Floor,

New York City, NY 10005,

United States

Phone: +1-929 297-9727

Email: [email protected]


Follow Us: LinkedIn | twitter



Cision View original content:–at-22-7-cagr-polaris-market-research-302032663.html

SOURCE Polaris Market Research

Disclaimer: The above press release comes to you under an arrangement with PR Newswire. takes no editorial responsibility for the same.